INmune Bio Inc. Reveals Phase 1 Data Showing XPro™ Dose-Dependent Effects on Synaptic Proteins in Alzheimer's Patients

BOCA RATON, Fla., July 29, 2024 — INmune Bio, a company at the forefront of inflammation and immunology treatment development, is proud to present new findings at the annual Alzheimer’s Association International Conference (AAIC) in Philadelphia, PA. Their recent poster presentation focuses on the proteomic analysis of cerebrospinal fluid (CSF) in Alzheimer's disease patients treated with XPro™ in a phase 1b study. The poster, titled "Dose-related modulation of the synaptic proteome after short-term treatment with XPro1595 for Alzheimer's disease," highlights substantial changes in synaptic proteins after a 12-week treatment period.

Synaptic proteins are crucial for neuron communication, and their loss begins early in Alzheimer’s disease, leading to severe cognitive decline. Dr. CJ Barnum, VP of Neuroscience at INmune Bio, explained, “The robust effect of XPro™ on a broad number of proteins and pathways that regulate synapse formation is consistent with what we have observed in preclinical models and what we expect to happen when normal/healthy immune function is restored.”

The formation and elimination of synapses are regulated by the innate immune system’s cells, such as astrocytes. In a dysregulated inflammatory state, synapse creation diminishes while elimination increases, disrupting neuron communication and leading to cognitive impairment in Alzheimer's disease. Restoring synaptic function requires a normally operating innate immune system.

Company CEO Dr. RJ Tesi noted, “We are encouraged by this new evidence of a treatment effect at the cellular level in proteins known to be affected by Alzheimer’s disease pathologies. XPro’s direct impact on synaptic proteins supports the improvement in synaptic function we recently observed with EEG data and provides further evidence that we are significantly restoring the immune system. This is yet another biological precursor to what we believe will lead to cognitive benefits, currently being tested in our ongoing Phase 2 trial.”

INmune Bio is actively conducting a phase 2 clinical trial in patients with mild to moderate Alzheimer’s disease, with top-line results expected in early 2025.

About XPro™

XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF), currently in clinical trials. Unlike existing TNF inhibitors, XPro™ specifically neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. This targeted approach aims to reduce neuroinflammation without causing immunosuppression, potentially offering significant benefits to patients with neurological diseases.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded clinical-stage company focused on developing treatments targeting the innate immune system to combat various diseases. The company has two main product platforms in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform and the Natural Killer Cell Priming Platform. The DN-TNF product platform uses dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction involved in many diseases. Current DN-TNF product candidates include INB03™ for cancer, and XPro™ for early Alzheimer’s disease and treatment-resistant depression. The Natural Killer Cell Priming Platform, including INKmune™, is designed to prime a patient’s NK cells to eliminate minimal residual disease in cancer patients. INmune Bio employs a precision medicine approach to treat a wide range of hematologic and solid tumor malignancies, as well as chronic inflammation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!